High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-Blind Randomized Placebo Controlled Clinical Trial

reportActive / Technical Report | Accession Number: ADA537750 | Open PDF

Abstract:

Antiretroviral therapy ART has transformed our clinical approach to human immunodeficiency virus HIV infection. Despite substantial advances in the management of HIV infection, concerns about transmitted drug resistance, ART-related toxic effects, and the consequences of chronic inflammation persist, emphasizing the need for ongoing research into alternate therapeutic targets and strategies to modulate the chronic immune activationinflammation observed in this disease 13. Strategies that block key interactions between the host and the virus, including those that target lipid rafts, are an area of interest. Lipid rafts are plasma membrane microdomains rich in sphingolipids and cholesterol that play a critical role in the replication of HIV type 1 HIV-1 4, 5. In vitro models suggest that disruption of lipid rafts with cholesterol-depleting agents, such as 3-hydroxy-3-methyl-glutaryl-coenzyme A HMG-CoA reductase inhibitors statins, reduces HIV-1 particle production 5.

Author(s):
Ganesan, Anuradha ; Crum-cianflone, Nancy ; Higgins, Jeanette ; Qin, Jing ; Rehm, Catherine ; Metcalf, Julia ; Brandt, Carolyn ; Vita, Jean ; Decker, Catherine F. ; Sklar, Peter ; Bavaro, Mary ; Tasker, Sybil ; Follmann, Dean ; Maldarelli, Frank
Author Organization(s):
NAVAL MEDICAL CENTER SAN DIEGO CA
Descriptive Note:
Journal article
Supplementary Note:
Published in the Journal of Infectious Diseases, v203 p756-764, 2011. Prepared in collaboration with Uniformed Services University, Bethesda, MD; SAIC, Frederick, MD; National Institute of Allergy and Infectious Diseases, Bethesda, MD; Drexel University, Philadelphia, PA; Merck Research Laboratories, North Wales, PA; Pharmaceutical Product Development Inc., Wilmington, DE; and National Cancer Institute, Frederick, MD. The original document contains color images.
Pagination:
0010

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Monitor Series:
XD
 Subject Terms
Joint Capability Areas:
JCA_5_Command and Control; JCA_5.3_Planning; JCA_5.3.3_Develop Strategy; JCA_5.3.4_Develop Courses of Action; JCA_5.3.5_Analyze Courses of Action; JCA_1.2.3_Educating
Communities of Interest:
No COI(s) Identified
Descriptor(s):
*HUMAN IMMUNODEFICIENCY VIRUSES, *RETROVIRUSES, CLINICAL MEDICINE, CHOLESTEROL, CHEMICAL AGENTS, MARKERS, CLINICAL TRIALS, INFLAMMATION, LIPOPROTEINS, RIBONUCLEIC ACIDS, CREATINE PHOSPHOKINASE, LIPIDS, CELLS, INFECTIOUS DISEASES
Field(s)/Group(s):
Medicine and Medical Research
Keyword(s):
ART(ANTIRETROVIRAL THERAPY), HIV(HUMAN IMMUNODEFICIENCY VIRUS), ATORVASTATIN, CELLULAR MARKERS, CPK(CREATININE PHOSPHOKINASE), CAD(CORONARY ARTERY DISEASE)
Report Date:
2011 Feb 15
Creation Date:
2011 Mar 16